Kriya muscle-directed AAV gene therapy (current KRIYA.288 programme)
Kriya Therapeutics
What it is
Kriya now lists KRIYA.288, an investigational muscle-directed AAV therapy carrying glucokinase to increase glucose-responsive glucose clearance. The sponsor labels it Phase 1/2, but no public T1D trial registration or human outcomes were located. Earlier KRIYA-839 insulin-plus-glucokinase reports should not be assumed to describe the same product.
Editorial review: .
Most recent recorded citation date: 2013-05-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Preclinical evidence. Benefit in people has not been established.
- Benefit or performance
- Efficacy: No human efficacy results for KRIYA.288 were located. Earlier animal work combining insulin and glucokinase cannot establish efficacy of the current glucokinase-payload product.[4]
- Important harms and treatment burden
- Safety: No public human safety results were located. A proposed single procedure does not establish that a gene therapy is safe or reversible.[1]
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Long-lasting glucose control in historical insulin-plus-glucokinase animal experiments does not demonstrate human durability for KRIYA.288.[4]
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. This speculative assessment includes intended performance or preclinical findings; it does not establish benefit in people.
Default calculation: 15 × 20 + 20 × 12 + 20 × 16 + 25 × 12 + 20 × 20 = 1560; divide by total weight 80. Unrounded weighted result: 19.5.
No human efficacy results for KRIYA.288 were located. Earlier animal work combining insulin and glucokinase cannot establish efficacy of the current glucokinase-payload product.[4]
Long-lasting glucose control in historical insulin-plus-glucokinase animal experiments does not demonstrate human durability for KRIYA.288.[4]
No public human safety results were located. A proposed single procedure does not establish that a gene therapy is safe or reversible.[1]
Current protocol eligibility has not been verified. Criteria from earlier media descriptions of KRIYA-839 cannot be transferred to KRIYA.288.[2]
Sponsor website labels KRIYA.288 Phase 1/2. A ClinicalTrials.gov sponsor search found four Kriya studies, none in T1D; trial initiation and dosing therefore remain unconfirmed in the public sources reviewed.[2]
Immunosuppression-free is scored here, as it is for cell replacement and encapsulation — freeing a therapy from lifelong anti-rejection drugs is the central barrier this whole pillar is trying to clear, so an approach that achieves it must be able to earn credit for it. It is scored on evidence, not intent: a platform designed to avoid immunosuppression but never yet tested at a therapeutic dose scores on what it has shown. Approaches that transplant nothing (in-vivo gene therapy, reprogramming) need no anti-rejection drugs by construction, but they still face the original autoimmune attack — that unresolved risk belongs in this score, not hidden by it.
The full picture
Current programme
Kriya's current primary source names KRIYA.288 and specifies a glucokinase payload, intended to help skeletal muscle clear excess glucose. It describes a one-time intramuscular procedure and labels development Phase 1/2. These are sponsor descriptions, not demonstrated human benefits.1
No T1D study appeared in the ClinicalTrials.gov sponsor search reviewed on 16 September 2026, and no participant outcomes were located. Registration or dosing elsewhere cannot be ruled out by that search.2
Why the older name and mechanism need care
Earlier reporting called the programme KRIYA-839 and described delivery of insulin plus glucokinase. Historical animal research tested that combination.34 The current page does not establish that KRIYA.288 is merely a rename. We retain this page's stable address, but do not transfer historical animal durability, proposed PROGRESS eligibility, or insulin-factory claims to the current product.
Coming soon
ETA · No verified outcome or approval date
- →Public protocol identifier, eligibility and confirmation of first dosing
- →Human safety, glucose-control and insulin-use results
Sources
- [1]KRIYA.288 Type 1 Diabetes — current programme specifications · Manufacturer — Reviewed 16 September 2026. Lists glucokinase payload, intramuscular outpatient administration and sponsor-designated Phase 1/2. Does not provide participant outcomes or a registry identifier.
Kriya Therapeutics. KRIYA.288 Type 1 Diabetes, reviewed 16 September 2026.
- [2]ClinicalTrials.gov sponsor search — Kriya · Trial registry — Reviewed 16 September 2026; four sponsor matches, none for T1D. Absence from this search is not proof that no trial exists elsewhere.
ClinicalTrials.gov sponsor search, reviewed 16 September 2026.
- [3]Gene Therapy to Be Studied for Treating Type 1 Diabetes (KRIYA-839) · Science journalism — Historical media description; not the source for current product specifications.
Medscape. Gene Therapy to Be Studied for Treating Type 1 Diabetes.
- [4]Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy · Peer-reviewed study · 2013-05-01 — Historical animal combination-gene-therapy evidence, not human KRIYA.288 results.
Callejas D, et al. Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy. Diabetes (2013).